VC
ABEO icon

Vivo Capital’s Abeona Therapeutics ABEO Stock Holding History

Vivo Capital’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,842,751
Closed -$9.71M – 47
2025
Q4 		$9.71M Hold
1,842,751
– – 0.63% 35
2025
Q3 		$9.73M Hold
1,842,751
– – 0.78% 33
2025
Q2 		$10.5M Hold
1,842,751
– – 1.07% 17
2025
Q1 		$8.77M Hold
1,842,751
– – 1.16% 20
2024
Q4 		$10.3M Hold
1,842,751
– – 1.15% 20
2024
Q3 		$11.6M Hold
1,842,751
– – 0.96% 21
2024
Q2 		$7.81M Buy
+1,842,751
New +$9.4M 0.72% 25

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vivo Capital's ABEO Position: Q1 2026 in Review

Vivo Capital sold out of Abeona Therapeutics (ABEO) in Q1 2026, closing a stake of 1,842,751 shares — an estimated $9.71M sold.

Vivo Capital first reported a position in ABEO in Q2 2024 and held it in 7 quarters. The position peaked at $11.6M in Q3 2024. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Vivo Capital reported no remaining Abeona Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Vivo Capital sold 1,842,751 Abeona Therapeutics shares in Q1 2026, an estimated $9.71M.
  • Vivo Capital first reported a position in Abeona Therapeutics in Q2 2024 and held it in 7 quarters.
  • Vivo Capital's Abeona Therapeutics position peaked at $11.6M in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.